L. Dracea (Brasov, Romania), B. Assael (Milan, Italy)
Sleep hypoxemia in cystic fibrosis M. V. Kakoura, D. Chloros, E. Fouka, S. Vogiatzis, G. Tsiaousis, M. Fotoulaki, G. Bompotis, S. Noussia-Arvanitakis (Thessaloniki, Greece)
| |
Detection and prediction of sleep hypoxia in children with cystic fibrosis N. Ozdemir, Z. S. Uyan, R. Ersu, B. Karadag, I. Akpinar, F. Karakoc, E. Dagli (Istanbul, Turkey)
| |
Walking distance, perceived physical functioning and respiratory problems in children with CF J. G. Nomden, M. M. v.d.Briel, E. J. L. E. Vrijlandt, E. van Weert (Groningen, Netherlands)
| |
Factors influencing the 6-min walking test in cystic fibrosis M. V. Kakoura, E. Fouka, D. Chloros, M. Fotoulaki, G. Tsiaousis, S. Vogiatzis, S. Noussia-Arvanitakis (Thessaloniki, Greece)
| |
Long-term administration of aerosolised tobramycin in patients with cystic fibrosis A. Chuchalin, K. Gyurkovics, H. Mazurek, G. Varoli, P. Monici Preti (Moscow, Russian Federation)
| |
Highly concentrated aerosolized tobramycin in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection G. Lenoir, N. Aryayev, G. Varoli, P. Monici Preti (Paris, France)
| |
Comparison of tobramycin 80 mg (IV-Preparation) and 300 mg solution for inhalation in cystic fibrosis patients W. H. Nikolaizik, D. Vietzke, F. Ratjen (Bad Lippspringe, Essen, Germany)
| |
Comparison between two protocols of preventing treatment of chronic Pseudomonas aeruginosa (Pa) infection R. Casciaro, A. De Alessandri, F. Lugani, E. Poggi, C. Gardella, G. Manno, L. Giampietri, M. Mentasti, R. Lorini (Genoa, Italy)
| |
Pneumothorax in paediatric cystic fibrosis patients G. Hafen, P. Robinson (Melbourne, Australia)
| |
Does I.V. continuous antibiotic treatment increase the risk of totally implantable vascular devices complications in CF? D. Sistek, M. Hofer, Y. Kernen, C. Schindler, A. Sauty (Lausanne, Switzerland)
| |
Endovascular stripping as a valuable tool to treat distal occlusions of totally implantable vascular devices in CF D. Sistek, M. Hofer, S. D. Qanadli, A. Sauty (Lausanne, Switzerland)
| |
Body mass index and fat-free mass in cystic fibrosis J. W. Wilson, S. King, T. Kotsimbos, I. Nyulasi (Melbourne, Australia)
| |
Reduced bone density in children and adolescents with cystic fibrosis M. Chriselis, F. Kirvasilis, E. Hatziagorou, E. Kazantzidou, J. Tsanakas (Thessaloniki, Greece)
| |
Silent and symptomatic gastro-oesophageal reflux in adults with cystic fibrosis J. W. Wilson, B. M. Button, T. Kotsimbos, M. Bailey, S. Roberts (Melbourne, Australia)
| |
Effects of cystic fibrosis on neurobehavioural function and driving task performance C. Dobbin, D. Bartlett, R. Grunstein, P. Bye (Sydney, Australia)
| |
Need for early intervention in cystic fibrosis - impact of an educational programme L. L. Dracea, O. Falup-Pecurariu (Brasov, Romania)
| |
Benefit of aerosol therapy with pulmozyme for children with cystic fibrosis S. Dumcius, A. Valiulis, L. Indrejaityte (Vilnius, Lithuania)
| |
Prognostic value of a high resolution computed tomography (HRCT) in cystic fibrosis children L. Jelenina, A. Orlov, I. Kondrashov (St. Petersburg, Russian Federation)
| |
Prevalence of renal impairment in an adult cystic fibrosis (CF) centre R. Rabbani, R. Mukherjee, J. L. Whitehouse, D. Honeybourne (Birmingham, United Kingdom)
| |
The study of expectant life of St-Petersburg patients with cystic fibrosis (CF) in 2002-2005 years A. G. Chermenskiy, T. E. Gembitskaya, L. A. Jelenina, T. S. Sologub, A. V. Orlov (St. Petersburg, Russian Federation)
| |